Epidemiology of Breast Cancer Presentation in Botswana, South Africa, and the United States.
Botswana
Breast cancer
Clinicopathology
Low-and-middle-income countries
South Africa
Journal
The Journal of surgical research
ISSN: 1095-8673
Titre abrégé: J Surg Res
Pays: United States
ID NLM: 0376340
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
09
10
2021
revised:
01
04
2022
accepted:
08
04
2022
pubmed:
23
7
2022
medline:
24
9
2022
entrez:
22
7
2022
Statut:
ppublish
Résumé
This study sought to compare the clinicopathologic features of women with breast cancer presenting in South Africa, Botswana, and the United States (US). Breast cancer samples from Botswana (n = 384, 2011-2015), South Africa (n = 475, 2016-2017), and the US (n = 361,353, 2011-2012) were retrospectively reviewed. The median age of sub-Saharan African women presenting with breast cancer (age 54 in Botswana and South Africa) was younger than that of those in the US (age 61) (P < 0.001). Sub-Saharan women were more likely to present with advanced stage disease than US counterparts (64.7% in Botswana, 63.3% in South Africa, 13% in the US, P < 0.001). Triple negative disease was highest in Botswana (21.3%) compared to South Africa (11.4%) and the US (12.94%) (P < 0.001). Differences in receptor status at presentation among the three cohorts (P < 0.001) were not observed when the cohorts were stratified by ethnicity. Black/multiracial patients in Botswana and the US were the most likely subsets to present with the adverse characteristic of triple negative disease (21.3% and 23.2%, respectively). No correlation was found between HIV and receptor status in the Botswana (P = 0.513) or South African (P = 0.352) cohorts. Here we report receptor status patterns at presentation in Botswana and South Africa. This study reveals important similarities and differences which may inform policy and provide context for future epidemiologic trends of breast cancer in low- and-middle-income countries particularly in sub-Saharan Africa.
Identifiants
pubmed: 35868037
pii: S0022-4804(22)00298-0
doi: 10.1016/j.jss.2022.04.071
pmc: PMC10033457
mid: NIHMS1876297
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
533-539Subventions
Organisme : NCI NIH HHS
ID : K08 CA230170
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI045008
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
PLoS One. 2015 Sep 01;10(9):e0134618
pubmed: 26325181
Eur J Public Health. 2017 Feb 1;27(1):173-178
pubmed: 28177503
Infect Agent Cancer. 2017 Feb 14;12:13
pubmed: 28228841
Breast Cancer Res. 2013;15(5):R84
pubmed: 24041225
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Glob Oncol. 2018 Sep;4:1-11
pubmed: 30241185
J Glob Oncol. 2018 Sep;4:1-7
pubmed: 30241141
J Surg Res. 2019 Mar;235:181-189
pubmed: 30691793
Int J Cancer. 2015 Mar 1;136(5):E470-4
pubmed: 25236502
Lancet Oncol. 2015 Aug;16(8):e414-21
pubmed: 26248849
S Afr J Surg. 2017 Mar;55(1):10-15
pubmed: 28876552
PLoS Med. 2014 Sep 09;11(9):e1001720
pubmed: 25202974
World J Clin Oncol. 2014 Aug 10;5(3):509-19
pubmed: 25114864
Womens Health (Lond). 2016 Jan;12(1):147-56
pubmed: 26757491
Breast Cancer Res Treat. 2013 Jul;140(1):177-86
pubmed: 23801159
Ann Surg Oncol. 2017 Oct;24(10):2869-2875
pubmed: 28766222
Breast. 2012 Aug;21(4):428-34
pubmed: 22289154
Lancet Oncol. 2013 Jul;14(8):e290-1
pubmed: 23816293
Breast Cancer Res Treat. 2014 Apr;144(3):467-78
pubmed: 24604092
Infect Agent Cancer. 2017 Sep 25;12:49
pubmed: 29021819
J Glob Oncol. 2019 Nov;5:1-16
pubmed: 31770052
Cancer Manag Res. 2018 Feb 09;10:279-286
pubmed: 29467582
J Clin Oncol. 2009 Sep 20;27(27):4515-21
pubmed: 19704069
J Natl Cancer Inst. 2014 Apr 28;106(5):
pubmed: 24777111
Reprod Health Matters. 2016 Nov;24(48):79-89
pubmed: 28024682